Sign up
Pharma Capital

PreveCeutical files two patents and looks to acquire human tissue for sol gel

PreveCeutical Medical Inc. (CNSX:PREV) Chairman and CEO Stephen Van Deventer joined Steve Darling from Proactive Investors to talk about the medical company that has recently filed two new patent applications for cyclic peptides and their use in pain management.

Van Deventer also talked about the company filing an application to a local hospital’s Human Ethics Committee to acquire human nasal mucosal tissue for the final phase of the cannabinoid-based, soluble gel. 

 

View full PREV profile View Profile
View All

© biotech Capital 2019

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.